Portfolio Company News
Taiwan Liposome Company approved for public status registrationOctober 05, 2010
SAN FRANCISCO and TAIPEI, September 23, 2010 - Taiwan Liposome Company (“TLC”) (http://www.tlcbio.com), a specialty pharmaceutical company with a proprietary drug delivery technology based on a lipid formulation platform, has received regulatory approval for public status registration and has been assigned the ticker identifier “4152”.
“We are delighted with this development for one of our portfolio companies,” said Dr. Ann Hanham, Managing Director, Burrill & Company “This approval paves the way for TLC to undertake the public offering. Taiwan is a region with an extremely tech-savvy investing public and we believe that the company’s proprietary drug delivery technology that enables the development and commercialization of new formulations of products with significant market potential will be well received.”
TLC, with operations in Taipei, Leiden and South San Francisco, is developing and commercializing a series of NCEs (New Chemical Entities) and “super-generics” with advantageous delivery or formulation characteristics. TLC’s lead product, ProFlow® (used to treat peripheral arterial disease and diabetic neuropathy), which is currently undergoing product development and registration in Asian markets, is a good demonstration of the company’s ability in developing super generics. In the area of NCE development, after the successful IND approval of Lipotecan® (oncology drug), which is receiving favorable results from the clinical trials in US and Taiwan, TLC will file another IND for its ophthalmic product, ProDex® (treatment of Macular Edema). The company’s ovarian and breast cancer treatment, Lipo-Dox®, is also marketed in Taiwan already.
“We are very excited about the forthcoming public offering,” said Dr. Hong, Founder & CEO of TLC “Our shareholders have always believed in TLC and gave us tremendous encouragements throughout the years, we are glad we’ll soon be able to reward them for their long-term support.” George Yeh, President of TLC, further commented “This milestone signifies a new phase for TLC, the Taiwan stock exchange market is a challenging and versatile one, we will strive to provide our investors with the best return possible.”
About Taiwan Liposome Company
Incorporated in 1997, Taiwan Liposome Company is a biopharmaceutical company engaging in research, development and commercialization of proprietary drug delivery system for improving the treatment of cancer, ophthalmic conditions, and infectious diseases. TLC founded and led by renowned scientist, Dr. Keelung Hong, who has over 30 years of research and development experience in liposomes with over 100 publications. TLC also has a team of researchers, management, production experts, and advisors who are building the company into an organization recognized for its excellence in targeted delivery and rapid advancement of products through the drug development process in South San Francisco, California and Taipei.
About Burrill & Company
Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report, which tracks the progress of the global biotechnology industry and annual “State of the Industry.” For more information, visit
Contact for Taiwan Liposome Company:
Tel: +886 (2) 2655 7377
Media Contact for Burrill & Company:
Tel: +1 (415) 591 5474